Cedars-Sinai researchers have pioneered a novel AI-driven approach for evaluating cardiovascular disease risk during standard chest CT scans, eliminating the need for contrast dye. Their study, published in Nature Communications, offers a promising avenue to cut costs and minimise invasiveness in identifying heart disease risk.
Utilising Available Data for Enhanced Risk Assessment
Conventionally, assessing cardiovascular risk involves costly and potentially risky contrast dye-enhanced CT scans. Yet, this approach poses financial and health concerns for some patients. Cedars-Sinai's research unveils AI's prowess in scrutinising standard CT data, emphasising coronary calcium levels and heart metrics to flag potential heart issues.
Involving nearly 30,000 patient records, the study showcases AI's superiority in detecting cardiac risks over traditional methods dependent on radiologists' visual evaluations of anomalies.
The Advantages and Promise of AI-Driven Risk Assessment
Sumeet Chugh, MD, Director of Cedars-Sinai's Division of Artificial Intelligence in Medicine, who wasn't part of the study, underscores the technology's potential. By tapping into existing CT scan data, AI enables large-scale screening to preemptively flag individuals prone to heart disease.
"Coronary artery disease is a global leading cause of disability and mortality," says Chugh, Smidt Heart Institute's associate director. "These results underscore how AI can repurpose existing CT images from lung disease assessments, making a cost-effective, public health difference in tackling heart disease."
Collaboration and Acknowledgements
The research represents a collaborative endeavour across various Cedars-Sinai departments, including the Smidt Heart Institute, the Biomedical Imaging Research Institute, and the Department of Biomedical Sciences. A comprehensive list of contributing researchers is available in the source material.
Supported by grants from the National Heart, Lung, and Blood Institute/National Institutes of Health (NHLBI/NIH) and the National Institute of Biomedical Imaging and Bioengineering, the study also acknowledges access to data from the National Lung Screening Trial (NLST) by the National Cancer Institute.
Piotr J. Slomka, PhD, Director of Innovation in Imaging at Cedars-Sinai, professor of Medicine in the Division of Artificial Intelligence in Medicine, and senior study author, highlights the transformative potential of the findings. "These results could significantly alter clinical practice for many patients, offering accurate cardiovascular risk assessment without the need for invasive tests or contrast dye, which some patients cannot tolerate."
Click here to read the original news story.